Technology Platform

New drug development

News Center

GMA301 was selected as “National Mega-Innovative Program

June, 2017, GMA301 was selected as the “National Mega-Innovative Program” for the 13th Five Year Plan. This designation is granted by the Chinese government to support domestic innovative molecules in financial support and registration priority review.

GMA102 IND registration accepted by CDE

February 6, 2017, CDE has accepted the IND registration of GMA 102. GMA102 is a humanized antibody against GLP-1R for type 2 diabetes and obesity. The phase I study of GMA102 is currently ongoing in Australia. Gmax has global right to this molecule.